Framework Journal · one stock, one dated entry

Recorded 2025-12-31 · Permanent

NuCana plc ADR NCNA

Outside both standards

An entry written while the outcome is still unknown. It will be scored by what the market does next, and it will never be edited to look cleverer than it was.

In plain words · NuCana plc, a clinical-stage biopharmaceutical company, engages in the development of medicines to treat patients with cancer in the United States.

The label
Distribution

read at $1.32

NuCana plc ADR holds its Distribution at $1.32.

PHINPOOPSC
  • PHPhase · the trend structure carries the Distribution label
  • INInsiders · no filings inside 60 days, left as found
  • POPositioning · no disclosures inside 60 days, left as found
  • OPOptions · no verdict drawn today, left as found
  • SCScreen · does not pass the values gate
  • edge confirmed
  • edge broken
  • edge forming

Each arm is one independent read. Conviction is not a single call, it is how many edges converge.

The investor read · the season, not the day

As held on the ledger · 2025-12-31
PhaseDistribution · caution
Quantitative stateConsolidating, no directional conviction, held for 227 days
Price$1.32
Valuation0.01 trailing · -0.14 forward price to earnings
Values screenFAIL · score 70.0
Beta2.24

The business, in plain words · what the numbers mean

The fundamentals · plain-English read
Forward P/E-0.1x
Trailing P/E0.0x
very cheap relative to earnings
Profit margin0.0%
currently unprofitable
Return on equity-231.7%
not currently earning a positive return on equity
Debt to equity3.04
heavy leverage — higher risk if revenue softens
Current ratio5.48
comfortably covers its short-term bills
Beta2.24
much more volatile than the market
Market cap$5M
Employees10

The risks · The things to watch: it's a small-cap, so the share price can swing harder than the market; it already moves more than the market on an average day; its business and earnings are exposed to United Kingdom and to currency swings; as a biotechnology name, trial and regulatory outcomes can move it sharply either way; it carries a real debt load, which raises the stakes if revenue slips.

Plain-English interpretation of our own screen data. Analysis, not advice.

Related securities · others in NCNA's space worth a look

Screened names in the same industry · explore each on its own page.

The trader read · the latest dated commentary

The framework has shifted from markdown to distribution since the last review. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 32.6% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it C. Technically it is sitting below its long-term trend line with momentum reading neutral. Over the past year the shares are down 93%. Our forward projection puts the odds of a 10% gain over the next month near 17%. Entered 2026-08-06 · Distribution

The dated journal · newest first, never edited

2026-08-06 Distribution · changed $1.32 -32.6% Entry 4

The framework has shifted from markdown to distribution since the last review. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 32.6% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it C. Technically it is sitting below its long-term trend line with momentum reading neutral. Over the past year the shares are down 93%. Our forward projection puts the odds of a 10% gain over the next month near 17%.

2026-07-18 Markdown $1.95 +0.0% Entry 3

The framework reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it C. Technically it is sitting below its long-term trend line with momentum reading neutral. Over the past year the shares are down 93%. Our forward projection puts the odds of a 10% gain over the next month near 17%.

2026-07-03 Markdown $1.95 +0.0% Entry 2

The framework reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen (70). The risk-adjusted return profile shows negative risk-adjusted returns.

2026-07-02 Markdown $1.95 Entry 1

The framework reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Ethical screening: PASS with passing ethical screen (70). The risk-adjusted return profile shows negative risk-adjusted returns.

Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.

What holding actually paid · price plus dividends

If $1,000 had been placed · historical, not a promise
PeriodPrice thenPrice returnDivs per share$1,000 becameTotal return
1 month $1.97 +0.0% · $1,000 +0.0%
2 months $1.97 +0.0% · $1,000 +0.0%
3 months $1.99 -1.0% · $990 -1.0%
6 months $4.05 -51.4% · $486 -51.4%
1 year $28.80 -93.2% · $68 -93.2%
2 years $630.00 -99.7% · $3 -99.7%
3 years $3,840.00 -100.0% · $0 -100.0%
5 years $15,000.00 -100.0% · $0 -100.0%

Historical returns from market close data. Past performance does not guarantee future results.

This entry now belongs to the ledger. Whatever NCNA does next, these words stay.

NuCana plc ADR · NCNA · Distribution · $1.32
Recorded 2025-12-31 · before the outcome · scored mechanically

Get our weekly market brief free.